⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KYMR News
Kymera Therapeutics, Inc. Common Stock
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis
globenewswire.com
KYMR
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering
globenewswire.com
KYMR
Kymera Therapeutics Announces Proposed Public Offering
globenewswire.com
KYMR
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
AMGN
PFE
LLY
AZN
BMY
NVS
SNY
GSK
UCB
ARQT
REGN
INCY
ABBV
BIIB
MRK
JNJ
VNDA
RAPT
CHAI
ONON
ION
ASMB
CRVS
APG
KSCP
KYMR
XBI
IBB
ADSK
CDNS
SNPS
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis
globenewswire.com
KYMR
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025
globenewswire.com
KYMR
Aluminum Metal Powder Market worth $2.64 billion by 2030 - Exclusive Report by MarketsandMarkets™
prnewswire.com
AMGGY
KYMR
NVTS
VALMT
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
globenewswire.com
KYMR
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
globenewswire.com
KYMR
Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update
globenewswire.com
KYMR